New drug shows promise for rare immune disorder
NCT ID NCT05063110
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tested the drug itacitinib in 35 adults with non-severe hemophagocytic lymphohistiocytosis (HLH), a rare immune condition. The goal was to see if itacitinib can control the disease by reducing symptoms within 15 days. Participants took the drug for at least 7 days, and the study measured how well it worked on clinical and lab signs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS PATIENTS HAVING NON SEVERE HLH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Avicenne
Bobigny, Bobigny, 93000, France
Conditions
Explore the condition pages connected to this study.